帕比司他的临床药代动力学与药效学
帕比司他是一种泛组蛋白去乙酰化酶抑制剂,与硼替佐米和地塞米松联用治疗多发性骨髓瘤。口服20 mg后约1小时达峰浓度21.6 ng/mL,绝对生物利用度21.4%,10–30 mg呈剂量比例暴露。肝功能损伤升高血药浓度,CYP3A4抑制剂、CYP3A4/CYP2D6诱导剂及P-糖蛋白抑制剂显著改变其AUC。
要点
- 轻中度肝功能损伤可考虑降低起始剂量,肾功能损伤无需调整。
- 帕比司他是CYP2D6抑制剂,可升高地塞米松血浆水平。
- CYP3A4抑制剂、CYP3A4/CYP2D6诱导剂及P-gp抑制剂显著改变帕比司他AUC。
核心结论
- 帕比司他药代动力学受肝功能、CYP3A4代谢及P-糖蛋白转运显著影响,联合用药需关注相互作用。
研究设计与样本
- 综述汇总多剂量药代动力学研究数据,未报告具体样本量。
主要发现
- 口服帕比司他20 mg后Cmax为21.6 ng/mL,约给药后1小时达峰,10–30 mg剂量范围内血浆暴露呈剂量比例。
- 绝对生物利用度为21.4%,血浆蛋白结合率为中等程度。
- 肾功能损伤不影响帕比司他固有药代动力学,肝功能损伤则升高其血浆浓度。
- 不同种族背景影响帕比司他药代动力学,但个体间变异大,不推荐剂量调整。
- 帕比司他AUC在CYP3A4抑制剂、CYP3A4和CYP2D6诱导剂及P-糖蛋白抑制剂存在下显著改变。
关键数值与推荐
- 轻至中度肝功能损伤患者可考虑以较低剂量起始治疗。
- 帕比司他为CYP2D6抑制剂,可影响CYP2D6底物地塞米松的血浆水平。
临床怎么用
- 启动帕比司他治疗前评估肝功能,轻中度损伤者考虑降低起始剂量。
- 合并使用CYP3A4抑制剂、CYP3A4/CYP2D6诱导剂或P-糖蛋白抑制剂时需警惕帕比司他暴露变化。
- 联用地塞米松时注意帕比司他抑制CYP2D6可能升高地塞米松水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Histone deacetylase (HDAC) inhibitors cause an increase in acetylation that leads to an increase in DNA transcription and accumulation of different proteins, reducing cell proliferation and inducing cell death. Panobinostat is a first-in-line HDAC inhibitor approved for treating multiple myeloma in combination with bortezomib and dexamethasone. It is a pan-deacetylase inhibitor and therefore inhibits not only HDAC but also other deacetylases. The main mechanism of action of panobinostat is to inhibit HDAC, which causes cell cycle arrest and apoptosis, leading to it being an antineoplastic drug. Pooled data of multiple-dose studies show that an oral dose of panobinostat 20 mg resulted in a maximum plasma concentration (C max) of 21.6 ng/mL approximately 1 h after administration, while doses between 10 and 30 mg resulted in dose proportional plasma levels. The absolute bioavailability of panobinostat is 21.4%, and it is moderately bound to plasma proteins. Renal impairment does not influence the intrinsic pharmacokinetics of panobinostat, however hepatic impairment causes an increase in the plasma concentrations of this drug. Therefore, starting treatment at lower doses could be considered in patients with mild to moderate hepatic impairment. Different ethnic backgrounds have an influence on the pharmacokinetics of panobinostat; however, due to major interindividual variability, no dose adjustment is recommended. The area under the concentration-time curve of panobinostat changes significantly under cytochrome P450 (CYP) 3A4 inhibitors, CYP3A4 and CYP2D6 inducers, and P-glycoprotein inhibitors. Panobinostat itself is a CYP2D6 inhibitor, which influences the plasma levels of the CYP2D6 substrate dexamethasone. The main side effects of panobinostat are diarrhea, peripheral neuropathy, asthenia and fatigue; hematologic side effects include neutropenia, thrombocytopenia, and lymphocytopenia.
引用
- Van Veggel M, Westerman E, Hamberg P, et al. Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat. Clin Pharmacokinet. 2018. PMID: 28667459. doi:10.1007/s40262-017-0565-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。